RDHL Redhill Biopharma Ltd.

9.02
+0.12  (1%)
Previous Close 8.90
Open 8.98
Price To book 3.15
Market Cap 153864594
Shares 17,058,159
Volume 72,369
Short Ratio 3.79
Av. Daily Volume 68,504

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1Q 2018.
RHB-104
Nontuberculous mycobacteria (NTM) infections
Phase 1/2 trial to be initiated 2H 2017.
MESUPRON
Pancreatic cancer
Phase 2a trial to be initiated 2H 2017.
YELIVA
Cholangiocarcinoma
Phase 1b to be initiated 2H 2017.
YELIVA
Prevention of mucositis in cancer patients undergoing therapeutic radiotherapy
Phase 1/2 trial initiation announced September 8, 2016. Announced that dosing has commenced - December 19, 2016.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Planned NDA resubmission due October 2017.
RIZAPORT (RHB-103)
Migraine
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Further analysis July 31, 2017 recommended trial continue as planned.
RHB-104 MAP US
Crohn’s disease
Phase 3 final data released March 2016. Additional Phase 3 trial initiation announced June 15, 2017.
RHB-105 - ERADICATE Hp 2
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Outcome from FDA Type B meeting due October 2017.
BEKINDA -GUARD
Gastroenteritis
Phase 2a data released December 12, 2016.
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2 top-line data due September 2017.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer
Phase 1/2 trial amended to include Kaposi sarcoma patients. Trial due to resume in late 2016.
YELIVA
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL)